Scheduled rituximab maintenance reduces relapse rate in eosinophilic granulomatosis with polyangiitis

Ann Rheum Dis. 2018 Jun;77(6):952-954. doi: 10.1136/annrheumdis-2017-211897. Epub 2017 Aug 16.

Authors

Giacomo Emmi^#¹, Giovanni M Rossi^#^{1

2}, Maria L Urban², Elena Silvestri¹, Domenico Prisco¹, Matteo Goldoni³, Augusto Vaglio²

Affiliations

¹ Interdisciplinary Internal Medicine, Careggi University Hospital, Firenze, Italy.
² Renal Unit, Parma University Hospital, Parma, Italy.
³ Department of Medicine and Surgery, University of Parma, Parma, Italy.

^# Contributed equally.

PMID: 28814426
DOI: 10.1136/annrheumdis-2017-211897

No abstract available

Keywords: ANCA-associated vasculitis; biologicals; eosinophilic granulomatosis with polyangiitis; rituximab.

Publication types

Letter

MeSH terms

Churg-Strauss Syndrome / drug therapy*
Humans
Immunologic Factors / therapeutic use*
Kaplan-Meier Estimate
Maintenance Chemotherapy / methods
Recurrence
Rituximab / therapeutic use*
Severity of Illness Index

Substances

Immunologic Factors
Rituximab